Entity
Description
  • Value proposition

    Transforming health, healthcare and drug discovery through the power of genomics

    We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery.

    We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening.

    Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes.

    In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems.

    Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).



    genomics, machine learning, drug discovery, and Precision Health

Corporate interactions BETA
Corporate TypeTweets Articles
Financial Times
Financial Times
Media, Newspaper Publishing
Financial Times
Media, Newspaper Publishing
Other

31 Dec 2023


Oxford Science Enterprises
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

9 Jan 2024


UK Atomic Energy Authority
UK Atomic Energy Authority
Research, National and local authorities
UK Atomic Energy Authority
Research, National and local authorities
Other

17 Dec 2022


AstraZeneca
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
Other

21 Oct 2017


Oxford University Innovation
Oxford University Innovation
Research, Financial Services
Oxford University Innovation
Research, Financial Services
Not capitalistic
Not partnership
Event

27 Sep 2018

23 Feb 2024



Biogen
Biogen
Biotechnology, Biotechnology Research
Biogen
Biotechnology, Biotechnology Research
Not capitalistic
Partnership
Not event

16 Oct 2017


Regeneron
Regeneron
Pharmaceutical, Biotechnology, Biotechnology Research
Regeneron
Pharmaceutical, Biotechnology, Biotechnology Research
Not capitalistic
Not partnership
Event

25 Jan 2017


Vertex Pharmaceuticals
Vertex Pharmaceuticals
Biotechnology, Biotechnology Research
Vertex Pharmaceuticals
Biotechnology, Biotechnology Research
Capitalistic
Partnership
Not event

30 Aug 2018


IP Group plc
IP Group plc
Financial Services
IP Group plc
Financial Services
Capitalistic
Partnership
Not event

2 Apr 2019

19 Feb 2024



Similar entities
Loading...
Loading...
Social network dynamics